Rheologics Technologies Inc (fka Rtgi)

[uwlungman]

Great pr out on 08/27...
KKS Venture Management Inc. Updates Capitalization Information
1:31p ET August 27, 2007 (Business Wire)
KKS Venture Management Inc. (OTC:KKSV) announces an update to its capitalization.

The Company is pleased to announce that it has reduced the number of shares issued and outstanding by half, without effecting any reverse stock split. The current issued and outstanding shares as of the date of this release are 214,210,173. The Company plans to continue strengthening through similar efforts that benefit the shareholder value.

About KKS

KKS Venture Management Inc. is a venture holding company, providing capital and consulting services to its partner companies. KKS focuses on emerging growth opportunities in the private and over the counter markets. The Company believes that the broad approach to managing its interest will bring the benefits of diversification and growth to its shareholders and partners.

Safe Harbor for Forward-Looking Statements: Except for historical information contained herein, the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in the future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, risk inherent in the Company's operations, imprecision in estimating product reserves and the Company's ability to replace and expand its interests. KKS Venture Management Inc. assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.

SOURCE: KKS Venture Management Inc.

KKS Venture Management Inc. Alfonso Knoll, 610-678-6900

[uwlungman]

Holding co. are good. At least no r/s. eom...

[gamood]

Rheologics Technologies Inc. Changes Its Name To KKS Venture Management Inc.
Mon Jul 23, 11:52 PM


EXTON, Pa.--(BUSINESS WIRE)--Rheologics Technologies Inc (OTC:RTGI) announces that it will be changing its name to KKS Venture Management Inc. The new trading symbol is OTC: KKSV. The name change reflects the Company’s renewed focus on diversifying its business interests to increase cash flow.

The Company will continue to manage its interests in Rheologics Inc. as well as other technologies while eliminating its obligation to provide capital and managerial support. The change comes in response to the Company’s desire to transition its interests out of research and development and into revenue producing projects. Rheologics Inc. will continue to focus on the development and commercialization of its medical technologies. To learn more about Rheologics please visit their website at www.Rheologics.com.

KKS Venture Management Inc. will function as a venture holding company, providing capital and consulting services to its partner companies. KKS will continue to focus on emerging growth opportunities in the private and over the counter markets. The Company believes that the broader approach to managing its interest will bring the benefits of diversification and growth to its shareholders and partners. The Company plans to launch a new website shortly.

Safe Harbor for Forward-Looking Statements: Except for historical information contained herein, the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in the future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, risk inherent in the Company's operations, imprecision in estimating product reserves and the Company's ability to replace and expand its interests. Rheologics Technologies Inc or KKS Ventures Inc. assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.

Rheologics Technologies Inc
Alfonso Knoll, 610-678-6900

[uwlungman]

Excellent news IMO. May be a good investment yet. eom...

[gamood]

Rheologics Technologies Inc. Announces Enhanced Strategy for the Future
Monday June 11, 4:47 pm ET

DENVER, PA--(MARKET WIRE)--Jun 11, 2007 -- Today Rheologics Technologies Inc. (Other OTC:RTGI.PK - News) announces enhancements to the Company's direction and strategy. The Company considers the changes necessary to preserve value for the shareholders. The strategy is focused on driving value and cash flow for the future.

After careful review, Rheologics Technologies Inc. has decided to focus on managing its technology and corporate interests with the goal of diversifying and growing its current holdings to produce cash flow. To that end, Rheologics Technologies Inc. has begun to explore the possibility of becoming a registered business development company (BDC). The Company's Board of Directors has also evaluated similar alternative strategies and expects to announce a formal structure shortly.

Over the next few days the Company expects to change its name and symbol to reflect the adapted model. In the short term, the Company will strive to voluntarily report, and hire auditors to be able to fully report. A new website will be launched to list its technology and business interests. And, additions to the Board of Directors will also be announced.

Rheologics Technologies Inc. is a development-stage company which for the past 23 months has been primarily focused on funding the research and development of blood flow technologies inside its subsidiary Rheologics Inc. In that time the subsidiary has produced little to no revenue nor is revenue expected in the foreseeable future. Rheologics Inc. continues to need significant working capital and research and development funding as it builds its blood flow technologies.

To eliminate the overwhelming cash drain and responsibilities related to the subsidiary, the Company has decided to reduce its holdings from a majority to a minority interest. Progress at Rheologics Inc. will continue to be monitored for potential future investment and equity management, but in the short term it will be a passive interest.

Safe Harbor for Forward-Looking Statements: Except for historical information contained herein, the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in the future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, risk inherent in the Company's operations, imprecision in estimating product reserves and the Company's ability to replace and expand its real estate interests. Rheologics Technologies Inc. assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.


Contact:

Contact:
Rheologics Technologies Inc.
Alfonso Knoll
610-678-6900


Source: Rheologics Technologies Inc.

[uwlungman]

Alphatrade, 10-day average vol = 1+ million...
Can that be true? It seems we hardly get any volume at all these days.

[ListenToMe]

we need to find out what the options are for the previous post.

[ListenToMe]

Rheologics Technologies Evaluating Strategic Directions



Last Update: 5:17 PM ET May 4, 2007


EXTON, PA, May 04, 2007 (MARKET WIRE via COMTEX) -- Rheologics Technologies, Inc. ("Rheologics" or the "Company") (PINKSHEETS: RTGI) today announced that management will be assembling a team to evaluate the strategic direction of the Company. Current management will seek to include representatives of third-parties and independent shareholders to evaluate the Company's core business and opportunities accurately and objectively.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.
Contact Rheologics: Teresa Shuler 800-969-2585
SOURCE: Rheologics Technologies, Inc.

[ListenToMe]

RTGI will be a nice rebound play!!!

[sojourner]

PRX: Good deal. Market declared a sale yesterday after careless dump of RTGI shares. Some of us were there to scoop up the basement bargains. Ole'!

[ListenToMe]

yup the cart is loaded as of right now 5-4-07 3:00 pm est.

[sojourner]

Anyone load the cart today?

[uwlungman]

Two trades (0.015 and 0.0148. So what do MMs do? Drop to 11? eom...

[CashFXGroupPowerTeam]

RTGI looking good on news today :)

[DAVE_007]

RTGI will pop big time on next good news..eom

[DAVE_007]

Stuffit..good to see you here!

personally, I have been doing pretty good..

but my mom has some health problems and
must take her to Chemo Doctor now..

I get back with ya later..

hold it in the road!

gotta run>>>...sorry..

[Tuff-Stuff]

Yes it does look ready Dave! How r ya?
And what ya been up to of late?

[DAVE_007]

RTGI weekly chart..looks ready!

[uwlungman]

Pr out. RTGI Multi-Center Clinical Study on Variations in Blood Viscosity

EXTON, PA, Apr 23, 2007 (MARKET WIRE via COMTEX) -- Rheologics Technologies Inc.
("Rheologics" or the "Company") (PINKSHEETS: RTGI), the leader in the study of
blood viscosity and its relationship to cardiovascular disease, announces plans
for a multi-center clinical study on the variability of whole blood viscosity.

Whole blood viscosity has been studied for over thirty years with approximately
1,000 papers published in peer-reviewed journals during that time period. This
body of research has correlated whole blood viscosity to numerous disease
conditions such as coronary and carotid artery disease as well as every major
cardiac risk factor, including blood pressure, LDL cholesterol, C-reactive
protein, age, and type-II diabetes.

With respect to this body of published work, Rheologics is responding to a need
for establishing standards for healthy ranges for whole blood viscosity and a
clearer understanding of the variability of whole blood viscosity in a broad
cross-section of patients.

Rheologics' Chairman & Chief Scientific Officer, Kenneth Kensey, MD, said, "This
multi-center study will be a vital foundation for future clinical and
pharmacological studies that will require reliable standards for healthy whole
blood viscosity, findings that have been historically unavailable in a definitive
fashion."

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical
technologies that improve the diagnosis and treatment of human disease. The
Company is accomplishing its mission by monitoring an overlooked basic
physiological parameter -- whole blood viscosity. Rheologics believes that its
innovations will ultimately enable the preventive diagnosis of diseases and the
development of new cost-effective therapies that conquer today's most difficult
medical problems, thereby improving the quality of life for millions of people
worldwide. Further information on Rheologics may be found at
http://www.rheologics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including but not limited to statements regarding the
Company's beliefs and expectations about the performance and benefits of its
technology; marketing and commercialization activities; and our beliefs regarding
research and development efforts. These forward-looking statements involve
certain risks and uncertainties that could cause actual results to differ. All
forward-looking statements herein are based on information available to us as of
the date hereof, and we undertake no obligation to update forward-looking
statements to reflect events or circumstances occurring after this date.

Contact:

ALLK Co.
Media Contact
Samantha Freire
646-671-1452
Email: Contact via http://www.marketwire.com/mw/emailprcntct?id=043505C429F04DEE

Rheologics, Inc.
Daniel Cho
800-969-2585




SOURCE: Rheologics Technologies, Inc.

Copyright 2007 Market Wire, All rights reserved.

[DAVE_007]

RTGI..grabbed a starter position yesterday..

Bottom?..

WEEK chart looks ready....

[uwlungman]

Looks nice for a change. Big UT would be nice too. eom...

[gamood]

"we could bounce off fridays close" Looks like we are still bouncing ...down the stairs! Maybe we'll hit a landing before we hit the basement!

[gamood]

Whole Blood Viscosity to Be Employed for Complications of Type II Diabetes
Monday April 16, 7:30 am ET

Rheologics Committed to Introducing Essential Measures to Identify, Treat and Counter Diabetic Complications

EXTON, PA--(MARKET WIRE)--Apr 16, 2007 -- Rheologics Technologies, Inc. ("Rheologics" or the "Company") (Other OTC:RTGI.PK - News), the leader in the study of blood viscosity and its relationship to cardiovascular disease, announces today its commitment to the development of measures to monitor and treat diabetes complications.

According to a new report called State of Diabetes Complications in America, poorly managed type II diabetes costs the U.S. healthcare system approximately $22.9 billion in 2006, in addition to the $37 billion deployed to treat type II diabetes itself. These complications include heart disease, stroke, eye disease, chronic kidney disease and foot problems that can lead to amputations. Nearly 21 million Americans have diabetes.

Rheologics is seeking to utilize its Rheolog® blood viscometer for the development of essential measures to identify, treat and counter diabetic complications. Underlying this target is the well-published but overlooked relationship between whole blood viscosity and type II diabetes. Since the 1977 publication of a British study connecting hyperviscosity to diabetic microcirculatory disease in Lancet, clinical researchers have suggested that elevated whole blood viscosity may be a treatable aspect of diabetic complications. Since then, a large number of studies have connected hyperviscosity in diabetics to eye and kidney disease as well as leg amputations and heart problems, including a 1994 Johns Hopkins Medical School review on diabetic eye disease and a 1997 Harvard Medical School study on diabetic kidney disease published in the American Journal of Hypertension.

Rheologics' Chairman & Chief Scientific Officer, Kenneth Kensey, MD, said:

"Whole blood viscosity plays an important role in the pathogenesis of cardiovascular disease, and diabetes mellitus often results in microcirculatory problems that are themselves major risk factors for cardiovascular disease. We believe the trigger in these cases may be hardened or non-deformable red blood cells, which are caused by osmolar imbalances brought about by a lack of blood glucose control. When the red blood cells are hardened, blood viscosity is sharply elevated and microangiopathy will take place -- disorders in the kidneys, the eyes, ulceration of the toes and feet, which all happen to be tissues of the body with very small capillary vessels. Non-deformable red blood cells that cannot easily pass through microvessels will damage the vasculature, causing disease to those organs of the body. Additionally type II diabetes increases cardiovascular risk, which Rheologics has maintained is also aggravated byhyperviscosity."

Rheologics' opportunity in identifying, monitoring and treating diabetic complications is a natural extension of its current plan to establish whole blood viscosity as a leading diagnostic test for cardiovascular disease. The Company is currently engaged in a clinical study on reducing leg amputation rates using viscosity-lowering therapy that includes diabetic patients and will seek to expand its clinical program to include patients with diabetic complications of the eye and kidney.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventive diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at www.rheologics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.


Contact:

Contact:
Rheologics
Daniel Cho
800-969-2585

ALLK Co.
Media Contact
Samantha Freire
646-671-1452
Email: Email Contact

[gamood]

Looks like somone got fed up with the direction of the PPS and decided to dump their shares!

[uwlungman]

UT with only trade so far at bid. Interesting. eom...

[uwlungman]

Alphatrade now has the news. Getting some upwards volume. eom...

[JIMWJ]

They will in time. This is a good direction for RTGI.
JWJ

[uwlungman]

We finally get a pr, and Alphatrade doesn't post it. eom...

[gamood]

Rheologics Adds New Management -- Mark Daugherty as Financial Controller
Tuesday April 10, 8:30 am ET

New Controller Skills and Experience Will Strengthen Company's Growth and Ongoing Financial Preparedness

EXTON, PA--(MARKET WIRE)--Apr 10, 2007 -- Rheologics Technologies, Inc., ("Rheologics" or the "Company") (Other OTC:RTGI.PK - News), the leader in the study of blood viscosity and its relationship to cardiovascular disease, announces today the addition of a new member to its management team, Mark H. Daugherty, as Financial Controller. In moving its business plan forward, Rheologics is continuously expanding and improving its ongoing R&D, laboratory services and revenue opportunities, each of which poses new challenges and opportunities for the future that a financial controller with Daugherty's experience is well-suited to address.

Rheologics' Chairman & Chief Scientific Officer, Dr. Kenneth Kensey, stated: "Up to now, Rheologics has ensured sound financial maintenance but as the Company continues to lay its foundation for the future as a leader in the development and commercialization of innovative medical technologies, we recognize the need to hire a designated expert who can precisely manage Rheologics' financial transitions."

Mark H. Daugherty

Mark joins Rheologics' management team after years of effectively managing separate business partnerships for Kenneth R. Kensey, MD, Rheologics' Chairman & Chief Scientific Officer.

Mark has over 25 years experience in financial services and brings extensive management background, including finance, banking and administrative skills developed in previous positions. He was the top financial executive for three previous employers with extensive experience in financial statement analysis, strategic planning, budgeting, forecasting and the presentation of the results to Senior Management and the Board of Directors. Mark holds a BS in Business Administration and Accounting.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventive diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at www.rheologics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.


Contact:

Contact:
Rheologics
Daniel Cho
800-969-2585

ALLK Co.
Media Contact
Samantha Freire
646-671-1452
Email: Email Contact


Source: Rheologics Technologies, Inc.

[gamood]

I have not see this much volume in awhile. No price movement but 322k of RTGI traded so far today!

[JIMWJ]

20 Million Float, approx 6000 shareholders per interview with COO.
JWJ

[JIMWJ]

I really like what I heard. I am sold on this.
JWJ

[uwlungman]

Outstanding interview. Great science. eom...

[gamood]

Listen to the interview with CEO Daniel CHO of RTGI...
http://www.meettheceo.com/interviews.php?id=32

[gamood]

Text version of interview with CEO Daniel CHO of RTGI...
http://www.meettheceo.com/web_page/text_version.php?id=32

[gamood]

I'm thinking today may be a good buying OP for RTGI. With another stock I own, the stock went up about 30% after a very positive interview!

[gamood]

Talked to the people at "Meet the Ceo" who are interviewing Daniel Cho. The interview will be about 45 min in length. Yesterday was the deadline for questions. The show will be PR'd Monday before the bell and you will be able to listen to the recorded interview at that time. Shareholders and interested individuals have submitted numerous questions, could be exciting!

http://www.meettheceo.com/

[gamood]

Rheologics President & COO Daniel Cho to Be Interviewed by Meet The CEO(TM)
Tuesday February 20, 7:30 am ET

Question Submission Available

EXTON, PA--(MARKET WIRE)--Feb 20, 2007 -- Rheologics Technologies, Inc. (Other OTC:RTGI.PK - News) ("Rheologics"), the leader in the study of blood viscosity and its relationship to cardiovascular disease, announced today that Company President and Chief Operating Officer Mr. Daniel Cho will be interviewed by Meet The CEO(TM) ('MTC') Friday, February 23rd. Mr. Cho will discuss the Rheolog®, the Company's new blood flow diagnostic technology, important trends in cardiovascular medicine, and the relevance of the Rheolog® in acute and preventive cardiology.

Shareholders and members of the media and brokerage community wishing to submit questions for consideration by Mr. Cho may do so in either of the following manners:

1) Call MTC's affiliate studio partner On Air, at (888) 88ONAIR (888-886-6247), ext. 28 and record your question when prompted. If chosen, your question will be audio-patched directly into the interview, or

2) Submit an email question, with reference to Rheologics, to [e-mail].

Questions need to be submitted via telephone or email no later than 6pm ET Thursday, February 22nd to be considered.

The interview will be posted as a streaming MP3 and Podcast download, and written transcript, on www.meettheceo.com 9am ET Monday, February 26th, 2006.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventative diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at www.rheologics.com.

About Meet The CEO(TM)

Meet The CEO(TM) provides a forum for domestic and international public and private companies, industry analysts and financial professionals to inform the business/investment community of their corporate models/areas of expertise, quarterly updates and fundamental milestones. The MTC environment affords executives and other specialized industry authorities a unique and innovative platform to articulate their insights, goals and opinions beyond the standard Wall Street pitch.

For further information, visit www.meettheceo.com or call 888.CEO.8899.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.


Contact:

Contact Rheologics
Daniel Cho
800-969-2585

Investor Relations
Jody Janson
ISD, Inc.
585-232-5440
http://www.istockdaily.com

Meet The CEO(TM)
Jennifer Gardiner
888-CEO-8899 (236-8899)
Direct: 403-618-9032
Email: Email Contact
http://www.meettheceo.com


Source: Rheologics Technologies, Inc.

[gamood]

Market News First's Interview of Rheologics President Now Available Online
Tuesday February 13, 2:46 pm ET

EXTON, PA--(MARKET WIRE)--Feb 13, 2007 -- Rheologics Technologies, Inc. (Other OTC:RTGI.PK - News) ("Rheologics"), the leader in the study of blood viscosity and its relationship to cardiovascular disease, announced that the interview of Daniel Cho, President of Rheologics, by Steve Kanaval on Market News First is now available online.

The interview can be heard by visit the following URL: http://www.mn1.com/members/modules.php?name=Downloads&d_op=getit&lid=725 or by downloading the podcast from Market News First's website at http://www.mn1.com.

During the interview, Mr. Cho answered questions touching on the importance of whole blood viscosity, an overlooked basic biological parameter that Rheologics believes is responsible for the efficiency and health of the cardiovascular system.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventative diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at www.rheologics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.


Contact:

Contact Rheologics:
Daniel Cho
800-969-2585
Email Contact

Investor Relations
Jody Janson - ISD, Inc.
585-232-5440
Email Contact
http://www.istockdaily.com

[gamood]

I agree, seems like good support at .04. To me, this is a good sign. Remember, we have plenty of investors that bought in the .02 to .04 range.

[Briboy]

pps holding steady

good sign

this week - come to papa

blessings,

briboy

[sojourner]

In my experience, it's generally proven beneficial not to believe those who claim to hear "little birdies." Agenda-driven, in the main.

[trump4]

I spoke with IR yesterday and was told there are no PR's expected...who knows?

[RickInv]

Yup, seems to be some sort of hold up here.

[trump4]

Maybe Friday for the news...I hope

[Stevenvegas]

okie doke

[RickInv]

Birdie says yes, news on the way! Last PR was late in the day, so maybe 3:00 or so...

[Stevenvegas]

Volume comin in. news comin?

[RickInv]

These guys gotta get a faster pencil!! Bring on da news already!

[Stevenvegas]

hearin news was out on bloomberg. Anyone see it?